Is Obesity Associated with an Increased Risk for Airway Hyperresponsiveness and Development of Asthma? by Sharma, Sat et al.
ORIGINAL ARTICLE
Is Obesity Associated with an Increased Risk for Airway
Hyperresponsiveness and Development of Asthma?
Sat Sharma, MD, FRCPC, Adarsh Tailor, MD, FRCPC, Richard Warrington, MD, PhD, FRCPC, and Mary Cheang,
M. Math
We investigated the association between airway hyperresponsiveness (AHR) and obesity in adults referred for confirmation of
asthma diagnosis. Data were analyzed for obesity class I (body mass index [BMI] 30234.9 kg/m
2), class II (BMI $ 35239.9 kg/m
2), and
class III (BMI $ 40 kg/m
2). Of 861 subjects, 401 demonstrated AHR; the mean dose of methacholine was 4.16 6 2.55 mg/mL. A
significant association between obesity and AHR was evident for all subjects: the odds ratio was 1.37 (95% CI 1.02–1.82; p 5 .0317).
One unit of increased BMI (1 kg/m
2) was associated with a 3.1% increase in AHR risk (95% CI 1.01–1.05, p , .005). The odds ratio
increased from 1.86 (95% CI 1.27–1.76; p 5 .0012) for class I to 2.61 (95% CI 1.48–4.60; p 5 .0006) for class III. Obesity was found to be
associated with AHR and appears to be a risk factor for asthma.
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R
ecently, asthma and obesity have evolved into two
major health concerns in developed countries.
1 Over
the past 20 years, obesity among adults and children has
risen significantly in the United States. The latest data from
the National Center for Health Statistics show that 30% of
US adults 20 years of age and older (over 60 million
people) and 16% of children and teens age 6 to 19 years
(over 9 million young people) are obese.
2 In addition,
current data overwhelmingly document the existence of a
worldwide asthma epidemic, although individual studies
remain controversial.
3–6 The epidemic is thought primarily
to involve persons with allergic asthma; numerous diverse
theories, based on an immunopathologic understanding of
the disease, have recently emerged to explain this
involvement. Thus, it appears that during the past three
decades, the prevalence of both asthma and obesity has
increased concurrently in Western countries, therefore
suggesting a possible link between the two.
7 Many
publications have shown an association between asthma
and obesity in adults and children.
7–10
Although obesity and asthma remain two of the fastest
growing and most pervasive public health problems in
developing countries, the question remains whether the
relationship of asthma to obesity is a real connection with
causal association or rather a misleading observation.
Many, but not all, of the studies have shown that the
association between obesity and the prevalence of asthma
diagnosis is stronger in women than in men.
9,10 Despite a
number of epidemiologic studies supporting an associa-
tion between asthma and obesity, controversy and
inconsistency in the literature remain. The majority of
studies support an association, but they are largely
observational in design and failed to use objective clinical
measures of asthma; therefore, they are susceptible to the
diagnostic and recall bias. The few studies that incorpo-
rated objective measures did not find an association.
10,11
Unfortunately, these studies included a relatively small
number of patients, and this may have precluded finding
an important difference. Additionally, confounding effects
of asthma medications used in the obese cohort may have
created a bias against an association being found. Although
many studies have supported the possible association
between obesity and asthma, the scientific literature
remains divided regarding the association between airway
hyperresponsiveness (AHR) and changes in body mass
index (BMI). A recent cross-sectional study of 86,144
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asthma prevalence. The study found that 1 unit of BMI
increase was associated with an approximately 6% increase
in asthma risk in women and a 3% increase in men. A
stronger association between obesity and asthma was
observed in non-allergic women than in allergic women.
12
No definite information on the BMI-adjusted trends in the
prevalence of asthma has been published in adults,
although data on asthma and BMI were obtained in the
National Health and Nutrition Examination Survey
(NHANES).
13
To further investigate the association between obesity
and asthma and its possible mechanisms, we investigated
the relationship of AHR, a marker of asthma, to obesity in
adult subjects. We hypothesized that in a large sample of
patients with respiratory symptoms suggestive of asthma
referred for confirmation of asthma diagnosis, a positive
association exists between BMI and AHR.
Methods
We evaluated all subjects referred for confirmation of
asthma by methacholine challenge test from 1999 to 2004
at the Pulmonary Function Tests Laboratory of St.
Boniface General Hospital, Winnipeg. Appropriate
Institutional Review Board and hospital approvals were
obtained. Based on symptoms, a diagnosis of asthma was
suspected by either the primary care physicians or
pulmonary specialists. The laboratory database prospec-
tively recorded demographic information, spirometry, and
methacholine challenge test data. The chronicled demo-
graphic information included age, sex, race, height, weight,
referring physician’s diagnosis, smoking history, medica-
tions, and history of cardiac disease. Evaluation of all
subjects and spirometric testing was done by experienced
pulmonary technologists certified and licensed by the
Canadian College of Respiratory Therapists and the
Canadian Association of Cardio-Pulmonary Technolo-
gists. In addition, the technologists validated the informa-
tion provided by the referring physician and documented
asthma history as part of the previously established
standard laboratory protocol. To minimize confounding
by other conditions in which (AHR) has been reported
(chronic obstructive pulmonary disease [COPD], sarcoi-
dosis, bronchiectasis, and cardiac disease and b-blocking
medications), we excluded these subjects. Additionally,
subjects with a history of smoking ($ 10 pack-years),
chronic steroid use, and suspected restrictive pulmonary
disease (forced vital capacity [FVC] , 80% predicted and
ratio of forced expiratory volume in 1 second [FEV1]t o
FVC $ 80%) were excluded from the study.
Spirometry was performed according to American
Thoracic Society criteria.
14 Testing was done with the
subjects seated, and a maximum forced exhalation was
carried out for a minimum of 6 seconds. After 6 seconds,
the test continued until zero flow was achieved (# 50 mL
flow extrapolated over 30 seconds). At least three FVC
manoeuvres were performed, two of which were repro-
ducible within 5%. Spirometric measurements were made
using the PFT Horizon System SensorMedics Corp. (Yorba
Linda, CA, USA); the machines were calibrated daily with
a 3 L volumetric syringe. All b2-agonist medications were
withheld at least 6 hours before testing. The methacholine
challenge test was performed in a standard fashion.
15 FVC
and FEV1 were measured after inhalation of normal saline
and after doubling concentrations of methacholine from
0.03 to 16.0 mg/mL in normal saline solution. The
methacholine solution was delivered using a Wright twin
nebulizer and inhaled by tidal breathing for 2 minutes with
the nose clipped. FVC and FEV1 were measured at 30 and
90 seconds after each dose. Doubling concentrations of
methacholine were administered at 5-minute intervals
until the FEV1 decreased by 20% from the lowest value
following saline solution FEV1 or until a dose of 16 mg/mL
was achieved. The provocative concentration of methacho-
line causing a 20% fall in FEV1 (PC20) was calculated by
linear interpolation of the last two points. The subjects
with a fall in FEV1 of 20% or more with less than 8 mg/mL
methacholine were defined as having AHR.
Obesity was defined as [BMI 5 weight (kg)/height (m)
squared (ht 3 ht) $ 30 kg/m
2]. Non-obese individuals
were defined as BMI , 30 kg/m
2. Obese individuals were
further classified as obesity class I, BMI from 30.0 to 34.9;
obesity class II, BMI from 35 to 39.9; and obesity class III
for BMI $ 40.0.
Statistical Analysis
Continuous variables were expressed as mean 6 SD.
Prevalence rates and mean values are reported with 95%
confidence intervals. The x2 test was used to determine the
significance of differences in prevalence across all BMI
groups and between different BMI groups, determined by
increasing cutoff values compared with their control
groups. Odds ratios (ORs), relative risks (RRs), and
attributable risks (ARs) (AR 5 risk ratio 2 1/risk ratio)
were estimated for AHR in the presence of obesity.
Correlates of BMI and AHR were studied with analysis of
variance (ANOVA) or Wilcoxon rank sum tests where
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as significant. The Cochran-Mantel-Haenszel test was also
used to stratify the results by gender. Pearson correlation
coefficient was used to assess the association between
continuous BMI and airway responsiveness. Two-way
ANOVA was used to analyze means of grouped data, and
least-square means post hoc analysis using the pooled
variance was also performed to correct for multiple
comparisons when comparing specific groups. The
Mantel-Haenszel trend test was performed as the data
suggested that there might be a dose-response trend.
Microsoft Excel and SAS version 9.1 (SAS Inc, Cary, NC)
were used for the data analysis.
Results
The analysis included 861 subjects: 337 (39%) were obese
and 401 (47%) demonstrated AHR (Table 1). The mean
methacholine dose (PC20) was 4.16 6 2.55 mg/mL.
Spirometric measurements of FVC, FEV1, and ratio of
FEV1 to FVC in methacholine-positive versus -negative
subjects were not statistically different. The mean FVC
(89.67 6 14.88 vs 92.14 6 15.40), mean FEV1 (98.93 6
15.34 vs 98.40 6 16.17), and mean ratio of FEV1 to FVC
(85 6 9.3 vs 81 6 9.5) were measured within the two
groups. There was a significant association between obesity
and AHR for all subjects; the OR was 1.37 (95% CI 1.02–
1.82; p 5 .0317). When used as a continuous variable in
logistic regression models, one unit of increased BMI
(1 kg/m
2) was associated with a 3.1% increase in AHR risk
(CI 1.01–1.05; p , .005) in all subjects. For men, this risk
was 3.4% (CI 1.01–1.06) for one unit of increased BMI
(1 kg/m
2) and for women 2% (CI 0.97–1.07), respectively.
The OR for point estimates of AHR risk in obesity was
1.09 (CI 0.76–1.54) for class I, 1.5 (CI 0.92–2.46) for class
II, and 2.78 (CI 1.56–4.94) for class III (Table 2). The
p values were .64 for class I, .10 for class II, and .0005 for
class III. When different thresholds for obesity were used
as cutoffs, the association became increasingly significant
as the level of obesity increased from class I to class III.
ORs for class I obesity were 1.86 (95% CI 1.27–1.76;
p 5 .0012) and for obesity class III were 2.61 (95% CI
1.48–4.60; p 5 .0006) (Table 3). Likewise, the RR increased
from 1.22 to 1.67 to 1.86 for obesity class I to class II and
class III, respectively. The attributable risk for the entire
group increased from 17.83 to 30.43 to 40.13% for obesity
classes I, II, and III, respectively. Using multiple regression,
for the positive methacholine challenge test, the age-
adjusted OR for BMI $ 30 was 1.44 (95% CI 1.07–1.93;
p 5 .014), for BMI $ 35 was 1.93 (95% CI 1.32–2.84; p 5
.007), and for BMI $ 40 was 2.71 (95% CI 1.54–4.79; p 5
.0006). The age-adjusted OR for the positive methacholine
challenge for a 1 kg/m
2 change in BMI was 1.037 (95% CI
1.01–1.06).
On stratifying data according to sex difference, we
found dissimilar results. For males, obesity class I did not
appear to be a significant risk factor. However, for higher
levels of obesity, classes II and III, there was a positive
association between obesity and AHR. The OR was 2.75
(95% CI 1.21–6.20) and the AR was 41% for class II
obesity in men, whereas the OR was 4.82 and the AR was
51% for males with class II obesity. In females, obesity was
a significant risk factor for AHR at all levels of obesity.
Class I obesity had an OR of 1.47 (95% CI 1.04–2.08) and
an AR of 22%, whereas a higher risk was observed with
obesity classes II and III, in which the ORs and ARs were
1.72 (95% CI 1.11–2.65) and 28% and 2.4 (95% CI
1.26–4.55) and 38%, respectively.
Table 1. Demographics of Total Evaluated and Included Patients
Characteristics Number (%)
Number of subjects evaluated 1,372
Number of subjects included 861 (63%)
Number of subjects excluded 511
Reasons of exclusion
COPD 293
Smoking history (. 10 pk-yr) 168
Restrictive lung disease 38
Congestive heart failure 12
Number of subjects with bronchial
hyperresponsiveness
401 (47%)
Number with obesity . 30 kg/m
2 337
Mean FVC (% predicted) in
subjects with AHR
89.67 6 14.88
Mean FEV1 (% predicted) in
subjects with AHR
98.93 6 15.34
AHR 5 airway hyperresponsiveness; COPD 5 chronic obstructive
pulmonary disease; FEV1 5 forced expiratory volume in 1 second; FVC
5 forced vital capacity.
Table 2. Point Estimates of Airway Hyperresponsiveness in All
Patients When Grouped as BMI 30 to 34.9, BMI 35 to 39.9, and
BMI $ 40 Compared with BMI , 30
BMI Odds Ratio 95% CI p Value
30–34.9 1.09 0.76–1.54 .64
35–39.9 1.50 0.92–2.46 .10
$ 40 2.78 1.56–4.94 .0005
BMI 5 body mass index; CI 5 confidence interval.
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We found obesity to be a significant risk factor for AHR in
subjects suspected of having asthma. According to the
Canadian Asthma Consensus Guidelines, asthma is defined
as ‘‘a disease characterized by paroxysmal or persistent
symptoms of dyspnea, chest tightness, wheezing, sputum
production, and cough associated with variable airflow
limitation and airway responsiveness to exogenous sti-
muli.’’
16 For epidemiologic purposes, asthma is defined as
current symptoms of dyspnea and/or wheeze within the
last 12 months, together with documented AHR.
17
The PC20 is usually interpreted in the context of
pretest and posttest probability of asthma.
18,19 The
subjects in this study were referred for confirmation of
asthma diagnosis because of respiratory symptoms,
thus carrying a high pretest probability of asthma.
Therefore, following a positive methacholine challenge
test (mean PC20 dose 5 4.16 6 2.55 mg/mL), a high
posttest probability of asthma in these subjects exists. AHR
has also been reported in patients with COPD.
20 However,
we excluded individuals with COPD based on spirometry
and smoking history. When analyzing data for sex
differences, similar to other published studies, we found
obesity to be a significant risk factor for AHR at all levels of
obesity for females but only for higher levels of obesity for
men.
11,21,22
Literature Review
Previous observational studies support an association
between AHR and asthma and obesity. Based on
Canadian National Population Health Survey data from
1994–1995, Chen and colleagues found that BMI values
were positively associated with prevalence of asthma in
women.
8 The adjusted OR was 1.52 for women with a BMI
of 28.0 kg/m
2 or more compared with those with a BMI of
20.0 to 24.9 kg/m
2. Shaheen and colleagues found that the
Table 3. Relationship to Airway Hyperresponsiveness in All Patients Using a Cutoff Value for Body Mass Index at 30, 35, and 40
BMI Age (yr)
% Methacholine
Positive Odds Ratio
95% CI for Odds
Ratio Relative Risk (CI)
Attributable
Risk (%) p Value
, 30 44.5 616.4 33.82 1.37 1.03–1.82 1.22 (1.02–1.45) 17.83 .0317
$ 30 49.1 6 14.2 41.16
, 35 45.7 6 16.1 34.24 1.86 1.27–1.76 1.67 (1.17–1.76) 30.43 .0012
$ 35 49.1 6 13.4 49.22
, 40 46 6 16 35.02 2.61 1.48–4.60 1.86 (1.31–2.13) 40.13 .0006
$ 40 49.5 6 11.3 58.49
BMI 5 body mass index; CI 5 confidence interval.
Table 4. Sex Differences for Airway Hyperresponsiveness Prevalence with Body Mass Index
Patient Attribute
Prevalence of AHR in Subjects
with BMI , 30 or $ 30
Prevalence of AHR in Subjects
with BMI , 35 or $ 35
Prevalence of AHR in Subjects with
BMI , 40 or $ 40
Female Male Female Male Female Male
BMI , 30 $ 30 , 30 $ 30 , 35 $ 35 , 35 $ 35 , 40 $ 40 , 40 $ 40
Total number of
subjects
382 230 153 96 496 100 234 31 555 41 250 15
% Methacholine
positive
33 42 36 39 34 47 35 59 35 56 35 73
Odds ratio (CI) 1.47 (1.04–2.08) 1.17 (0.70–1.98) 1.72 (1.11–2.65) 2.75 (1.21–6.20) 2.40 (1.26–4.55) 4.82 (1.25–18.6)
p Value .03 .54 .01 .01 .006 .01
Relative risk 1.27 1.12 1.38 1.71 1.61 2.04
Attributable risk
(%)
22 10 28 41 38 51
AHR 5 airway hyperresponsiveness; BMI 5 body mass index; CI 5 confidence interval.
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adults were higher in overweight women.
9 ORs were 1.51
in those with a BMI of 25.0 to 29.9 kg/m
2 and 1.84 in those
with a BMI of at least 30.0 kg/m
2 compared with those
with a BMI less than 25.0 kg/m
2. Luder and colleagues
reported similar associations between BMI and physician-
diagnosed asthma based on data from 5,527 adults living
in New York State.
10 Several longitudinal epidemiologic
studies have yielded similar results.
8–12 Findings from the
Nurses’ Health Study suggest that a 25 kg weight gain was
associated with a 2.5-fold increase in the risk for diagnosis
of asthma compared with no significant weight gain.
11 In a
cross-sectional analysis of 18,000 children aged 4 to 11
years, Figueroa-Munoz and colleagues showed that asthma
diagnosis and BMI were positively associated (OR 5 1.29,
95% CI 1.13–1.47).
21 Gilliland and colleagues showed that
the risk of new-onset asthma was higher among obese
children (RR 5 1.60, 95% CI 1.08–2.36) and found this
effect to be stronger in boys.
22
Other investigators did not find such an associa-
tion and thus speculated that asthma might be over-
diagnosed in obese subjects. Schachter and colleagues
studied 1,971 Australian adults in a cross-sectional
epidemiologic study and found that obesity was a
significant risk factor for diagnosis of asthma (OR 5
2.04), wheeze, and asthma medication use (OR 5 2.83)
but not for AHR, atopy, or airflow obstruction.
23 Despite
more symptoms consistent with asthma and use of more
asthma medications in severely obese subjects, the level of
AHR and airflow obstruction did not support higher
prevalence of asthma. Sin and colleagues examined data
from NHANES III and showed that the most obese
participants (BMI . 31 kg/m
2) had the greatest risk of
self-reported asthma, dyspnea, and bronchodilator use
but paradoxically were found to have lower risk for
airflow obstruction.
13 Obese subjects used more bronch-
odilators than non-obese subjects without objective
evidence of airflow obstruction, and asthma was over-
diagnosed in this obese population. In a cross-sectional
study of 86,144 Canadians who were 20 to 64 years of age,
a stronger association between obesity and asthma was
observed in non-allergic women than in allergic women,
with the adjusted ORs being 2.53 (95% CI 2.11–3.04) and
1.57 (95% CI 1.36–1.82), respectively.
12
Biological Plausibility
To establish causality between obesity, asthma, and BHR,
plausible biological mechanisms must be proved to
support this hypothesis. Obesity may directly affect
individuals with asthma predisposition by direct mechan-
ical effects, by immune response enhancement through
related genetic mechanisms, and by sex-specific hor-
mones.
24 Since obesity is intricately linked to environ-
mental factors such as physical activity, diet, and birth
weight, these environmental influences, in combination
with genetic predilection, may then lead to enhanced
susceptibility to asthma. Undoubtedly, obesity is known
to produce symptoms of dyspnea and wheezing;
whether asthma and airflow obstruction are responsible
for these symptoms has not been conclusively ascertained.
The reduced chest wall compliance in obesity causes a
substantial elastic load on inspiratory muscles and
increases the work and the energy costs of breathing.
25,26
Obesity induces a reduction in functional residual
capacity (FRC) and decrements in tidal volume, which
fail to increase during exercise.
27 Thus, waning FRC and
tidal volumes may result in alterations in the airway
smooth muscles and hence increased airways resistance
and methacholine reactivity. Therefore, obese patients
complain of more dyspnea and asthma-like symptoms
than leaner patients and may be incorrectly diagnosed
with asthma.
28,29 In addition, obesity has been associated
with decrements in forced expiratory flow (FEF) in the
midportion of FVC (FEF25–75). The ratio of FEF25–75
to FVC has also been independently associated with
methacholine responsiveness of the airways.
30 Gas-
troesophageal reflux (GER) is commonly seen in patients
with asthma; the prevalence of GER is estimated to be 60
to 80%.
31 Since obesity has been frequently cited as an
independent risk factor for GER, one may speculate that
GER might mediate the relationship between asthma and
obesity.
Asthma and obesity are both inflammatory states.
16
Allergic asthma is characterized by elevation of the
cytokines interleukin (IL)-4 and IL-5, which are respon-
sible for the inflammatory cells infiltrating the airways.
32
Tumour necrosis factor a (TNF-a), IL-1b, and IL-6 are
also increased in asthmatics. Obesity is also a chronic
inflammatory state.
33 Fat cells (adipocytes) are an
important endocrine organ that produces a number of
compounds that regulate inflammation such as IL-1b,
IL-6, TNF-a, leptin, and adiponectin.
34 Animal studies
indicate that elevations in IL-6 may contribute to
upregulation of inflammation in airways, independent of
an allergic mechanism. IL-6 increases production of
prostaglandin E2 (PGE2), stimulating the humoral
immune system and production of T-helper 2 (Th2)-
associated cytokines.
35 PGE2 does this by modulating
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tion, maturation, and ability to secrete cytokines.
36 PGE2 is
a potent inducer of IL-10 in bone marrow–derived
dendritic cells, and this cytokine displays both immunos-
timulatory and immunoregulatory activities.
37 PGE2 can
also act on immature dendritic cells to trigger local Th2
recruitment via control of cytokine production.
38 The
hormone leptin of the IL-6 family has effects on
inflammation, including the release of IL-6 from macro-
phages and lymphocytes.
39,40 Leptin levels in adulthood
are higher in women than in men, along with a higher
prevalence of asthma.
41 But the specific role of leptin and
the recently described adipocytokines, such as adiponectin,
resistin, and visfatin, remains undefined.
42
Interestingly, in most but not all studies, BMI has not
been independently related to atopy, so the effects of
obesity, other than immune mechanisms, are mediated
through hormonal influences. The study by Huang and
colleagues showed that girls in the highest BMI quintile
had a significantly higher prevalence of atopy and rhinitis
symptoms than girls in the lowest BMI quintile.
43 In
contrast, Jang and colleagues and Jarvis and colleagues
found no association between BMI and atopy.
44,45 In a
study of children with a mean age of 5.9 years, Guler and
colleagues found that atopic asthmatics had significantly
higher leptin levels for a similar BMI than non-atopic
asthmatics, but this did not correlate with skin test
reactivity.
46 An explanation for these disparities may
come from the study of Vieira and colleagues, who
found that in healthy obese and non-obese women,
specific immunoglobulin E (IgE) was three times higher
in obese compared with non-obese subjects, as were
plasma 17b-estradiol, fasting insulin resistance, C-peptide,
and leptin concentrations.
47 All of these factors correlated
with fat mass, which was the only positive predictor of
specific IgE. Thus, female sex hormones may also play a
role, given the increased risk of asthma development in
women.
48 The effect of female hormone levels may also
be related to our findings of significant BHR in obesity
class I compared with men. Obesity may reduce proges-
terone, which would reduce b2-receptor function, which
may reduce bronchial smooth muscle relaxation and
worsen asthma control. Weight loss increases progesterone
and adrenoreceptor density and improves lung function in
obese females with asthma. Although some effect of
estrogen levels on airways responsiveness is seen in
animal modes, it is not clear which airway cells express
estrogen receptors and/or if signalling pathways via
estrogen receptors interact with airway inflammation in
asthma.
49,50
Implications of Obesity and Asthma Causality
Our and other epidemiologic investigations denote a
significant temporal relationship between alterations in
body mass and asthma. This association is probably
multifactorial; however, the potential independent effects
of biomechanics, inflammation, genetics, and sex-specific
effects contradict this association. Research is urgently
needed to further elucidate this relationship and under-
stand the causal mechanisms of obesity and asthma
association. From a public health standpoint, these studies
have substantial implications. If asthma were added to the
list of conditions related to obesity, then reducing the
prevalence of obesity could be expected to produce even
greater public health benefits than are currently estimated.
It may be too early to incorporate weight reduction
strategies in efforts to reduce the health and economic
burden of asthma; however, current evidence mandates
that such interventions should not be delayed either.
Limitations of Our Study
Ours is an observational cohort study that includes
inherent limitations, such as the lack of an age- and sex-
matched control group, its retrospective nature, relatively
small sample size, and inability to categorize clinical
asthma severity. All patients included in this study were
referred to a tertiary care centre for evaluation of
respiratory symptoms, therefore creating a selection bias.
Despite these limitations, our study attained some
important observations, which can have potential implica-
tions in designing future health policies.
Conclusion
In summary, obesity and asthma are the two fastest
growing health problems worldwide; there appears to be a
genuine association between the two. Our study estab-
lished obesity as a risk factor for new diagnosis of asthma,
the risk increasing with higher levels of obesity. These
findings should be the basis for future controlled
investigations to further establish this association and
discover the biological mechanisms for their association.
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